Using murine BCP-ALL Lgals3-/- cells, we previously showed that the ability to produce endogenous Galectin-3 provides protection to the BCP-ALL cells against chemotherapy [26]. This evidence concerns the gene LGALS3 and acute lymphoblastic leukemia.